<- Go home

Added to YB: 2025-01-31

Pitch date: 2025-01-07

BVNRY [bullish]

Bavarian Nordic A/S

+11.23%

current return

Author Info

No bio for this author

Company Info

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.

Market Cap

DKK 14.1B

Pitch Price

DKK 9.08

Price Target

N/A

Dividend

N/A

EV/EBITDA

6.49

P/E

10.46

EV/Sales

1.75

Sector

Biotechnology

Category

growth

Show full summary:
Protean Small Cap New Position: Bavarian Nordic A/S

BVNRY: Danish vaccine co. Strong travel vaccine franchise (rabies, TBE) growing. TBE benefits from climate change. Potential for acquisitions in neglected travel vaccine segment. Jynneos (smallpox/monkeypox) adds optionality. Consolidating production to improve margins by 2025. Reduced risk profile with growing core business.

Read full article (1 min)